Delisting riskPopularity #5,362
RVPH · NASDAQ · Biotechnology

Reviva Pharmaceuticals (RVPH)

Develops brilaroxazine-led therapies for CNS, inflammatory, and cardiometabolic diseases.

$0.5040
vs last close−0.02 (−4.55%)